Cabezas SY

Language: Spanish
References: 10
Page: 381-383
PDF size: 197.61 Kb.

ABSTRACT

Neuroleptic Malignant Syndrome is the result of the use of neuroleptic drugs, which generate a metabolic disorder secondary to antagonism of dopamine receptors in the hypothalamus.

REFERENCES

1. Caroff SN. Mann SC. Neuroleptic malignat síndrome. Med. Clin N Am 1993,7 185-202.

2. Ferri: Practical Guide to the Care of the Medical Patient, 8th ed.; Chapter 3 - Diseases and Disorders

3. Goldman: Cecil Medicine, 23rd ed.; Chapter 460 - MEDICAL CONSULTA-TION IN PSYCHIATRY >> MEDICAL COMPLICATIONS OF PSYCHIATRIC TREATMENTS.

4. Hunford. William E. “Massachusetts General Hospital Anestesia”. Edición original. Editorial Marbon Libros S.A. 2005. Pag 291-292.

5. Jacobson: Psychiatric Secrets, 2nd ed.; Chapter 48 - ANTIPSYCHOTIC MEDICATIONS

6. Jacobson: Psychiatric Secrets, 2nd ed.; Chapter 77 - NEUROLEPTIC MALIG-NANT SYNDROME

7. Revista Médica de Chile, Santiago octubre 2005.

8. Shannon: Haddad and Winchester’s Clinical Management of Poisoning and Drug Overdose, 4th ed.; Chapter 10 - Clinical Neurotoxicology > ... > NEUROLEPTIC MALIGNANT SYNDROME

9. Stern: Massachusetts General Hospital Comprehensive Clinical Psychiatry, 1st ed.; CHAPTER 55 - Catatonia, Neuroleptic Malignant Syndrome, and Serotonin Syndrome.

10. Wikipedia (2010). Síndrome Neuroléptico Maligno. Obtenida el 10 marzo 2011, de http://es.wikipedia.org/wiki/Síndrome_neuroléptico_maligno.